Stock Scorecard
Stock Summary for Centessa Pharmaceuticals plc (CNTA) - $22.41 as of 10/15/2025 8:35:46 AM EST
Total Score
6 out of 30
Safety Score
39 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for CNTA
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for CNTA
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for CNTA
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for CNTA
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for CNTA (39 out of 100)
| Stock Price Rating (Max of 10) | 7 |
| Historical Stock Price Rating (Max of 10) | 5 |
| Stock Price Trend (Max of 10) | 9 |
| Book Value (Max of 10) | 3 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 5 |
| Analyst Strong Buy Ratings (Max of 5) | 4 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 6 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for CNTA
Financial Details for CNTA
Company Overview |
|
|---|---|
| Ticker | CNTA |
| Company Name | Centessa Pharmaceuticals plc |
| Country | USA |
| Description | Centessa Pharmaceuticals PLC is an innovative biotechnology company based in Cambridge, UK, focused on transforming the therapeutic landscape through its unique drug discovery and development platform. Leveraging a diversified portfolio of product candidates across multiple therapeutic areas, including oncology and rare diseases, Centessa is committed to addressing unmet medical needs by advancing a pipeline of novel therapies. The company's strategic approach combines pioneering scientific research with a deep understanding of patient and market needs, positioning it as a key player in the biopharmaceutical industry. |
| Sector Name | HEALTHCARE |
| Industry Name | BIOTECHNOLOGY |
| Most Recent Quarter | 6/30/2025 |
| Next Earnings Date | 11/17/2025 |
Stock Price History |
|
| Last Day Price | 22.41 |
| Price 4 Years Ago | 11.26 |
| Last Day Price Updated | 10/15/2025 8:35:46 AM EST |
| Last Day Volume | 717,640 |
| Average Daily Volume | 1,391,548 |
| 52-Week High | 24.57 |
| 52-Week Low | 9.60 |
| Last Price to 52 Week Low | 133.44% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 22.31 |
| Sector PE | 40.41 |
| 5-Year Average PE | -12.51 |
| Free Cash Flow Ratio | 67.91 |
| Industry Free Cash Flow Ratio | 14.26 |
| Sector Free Cash Flow Ratio | 29.23 |
| Current Ratio Most Recent Quarter | 10.12 |
| Total Cash Per Share | 0.33 |
| Book Value Per Share Most Recent Quarter | 2.58 |
| Price to Book Ratio | 8.96 |
| Industry Price to Book Ratio | 29.98 |
| Sector Price to Book Ratio | 32.01 |
| Price to Sales Ratio Twelve Trailing Months | 199.41 |
| Industry Price to Sales Ratio Twelve Trailing Months | 30.64 |
| Sector Price to Sales Ratio Twelve Trailing Months | 15.78 |
| Analyst Buy Ratings | 10 |
| Analyst Strong Buy Ratings | 2 |
Share Statistics |
|
| Total Shares Outstanding | 134,073,000 |
| Market Capitalization | 3,004,575,930 |
| Institutional Ownership | 93.35% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | -56.04% |
| Reported EPS 12 Trailing Months | -1.85 |
| Reported EPS Past Year | -0.58 |
| Reported EPS Prior Year | -1.99 |
| Net Income Twelve Trailing Months | -230,373,000 |
| Net Income Past Year | -235,757,000 |
| Net Income Prior Year | -151,085,000 |
| Quarterly Revenue Growth YOY | 0.00% |
| 5-Year Revenue Growth | 0.00% |
| Operating Margin Twelve Trailing Months | -1,376.00% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 44,242,000 |
| Total Cash Past Year | 383,221,000 |
| Total Cash Prior Year | 128,030,000 |
| Net Cash Position Most Recent Quarter | -65,303,000 |
| Net Cash Position Past Year | 274,281,000 |
| Long Term Debt Past Year | 108,940,000 |
| Long Term Debt Prior Year | 75,700,000 |
| Total Debt Most Recent Quarter | 109,545,000 |
| Equity to Debt Ratio Past Year | 0.79 |
| Equity to Debt Ratio Most Recent Quarter | 0.76 |
| Total Stockholder Equity Past Year | 401,545,000 |
| Total Stockholder Equity Prior Year | 236,244,000 |
| Total Stockholder Equity Most Recent Quarter | 344,919,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -144,047,005 |
| Free Cash Flow Per Share Twelve Trailing Months | -1.07 |
| Free Cash Flow Past Year | -142,089,000 |
| Free Cash Flow Prior Year | -160,511,000 |
Options |
|
| Put/Call Ratio | 0.25 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 0.86 |
| MACD Signal | 1.21 |
| 20-Day Bollinger Lower Band | 9.65 |
| 20-Day Bollinger Middle Band | 17.34 |
| 20-Day Bollinger Upper Band | 25.03 |
| Beta | 1.57 |
| RSI | 51.78 |
| 50-Day SMA | 16.09 |
| 150-Day SMA | 10.59 |
| 200-Day SMA | 9.54 |
System |
|
| Modified | 10/13/2025 8:39:40 PM EST |